Press Alt+1 for screen-reader mode, Alt+0 to cancelAccessibility Screen-Reader Guide, Feedback, and Issue Reporting | New window

Stock News

Mustang Bio’s Shares Skyrocket as FDA Grants Orphan Drug Designation

Bryce TuoheyAvatar
Written by Bryce Tuohey
Updated 7/9/2025, 11:32 am ET | 4 min

In this article

  • MBIO0.00%
    MBIO - NASDAQMustang Bio Inc.
    $1.650.00 (0.00%)
    Volume:  32967
    Float:  6.23M
    $1.61Day Low/High$1.68

Mustang Bio Inc.’s stocks have been trading up by 14.47% amid investor optimism fueled by significant FDA designations.

  • The designation marks a major milestone, affirming MB-101’s potential. Enhancing clinical outcomes is supported by promising data from Phase 1 trials.

  • The upward surge of 222% in shares reflects investor excitement and confidence in Mustang Bio’s strategic advancements in the high-stakes field of CAR T-cell therapy.

Candlestick Chart

Live Update At 11:32:14 EST: On Wednesday, July 09, 2025 Mustang Bio Inc. stock [NASDAQ: MBIO] is trending up by 14.47%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Mustang Bio Inc., recently, exhibited a roller-coaster performance in stock price due to groundbreaking announcements. Despite this, there remains an underlying volatility around their stock, indicative of their current financial health and investor sentiment.

  • For Q1 2025, Mustang Bio has operated with significant cash flow activities that have drawn a mixed bag of reactions from investors. With an operating cash flow of -$1.39M and free cash flows negative as well, it’s evident the company is heavily investing in its R&D endeavors.

  • Despite a net income loss of $153,000, recent FDA recognition provides an expectation of potential revenue increases, mainly from MB-101, possibly reversing cash flow woes.

  • Financial health is precariously balanced. There’s a positive cash position of $14.23M, yet with profitability ratios pointing towards loss margins, the focus rather is on leveraging upcoming drug potentials to positively impact future profits.

The various reports reveal a shaky financial foundation, though one lifted by strategic milestones that promise long-term revenue if successfully navigated. Current ratios reflect limited liquidity, but with pivotal developments like the new drug approval providing optimism about impacting revenue, there’s a shift in sentiment towards growth.

Enhancements in CAR T-Cell Therapeutic Development

Following Mustang Bio’s stellar FDA announcement, it isn’t just about winning regulations, but engraining itself with future markets. They are cementing a noteworthy footprint within the competitive landscape of CAR T-Cell therapy development. By securing orphan drug designation, Mustang sets itself in a beneficial position, highlighting not only their drug discovery model but aiming for breakthroughs.

Industry competition is high. Mustang’s MB-101, alongside hopeful outcomes with another candidat, MB-108, aims at becoming a game-changer. Through regulatory backing, they harbor an optimistic stand, buoyed by positive insights projecting them at frontline ranks in biopharmaceutical innovations.

More Breaking News

Conclusion

Mustang Bio’s recent ordeal is a testimony to a well-played strategic move targeting legislative advantages in the pharmaceutical sphere. This doesn’t diminish the financial succumb of the ongoing R&D expenses, feeding through open questions on sustainability but can instead offer glimpses of prosperity courtesy of scientific advancements. As millionaire penny stock trader and teacher Tim Sykes, says, “It’s better to go home at zero than to go home in the red.” This mindset reflects the cautious approach being adopted by Mustang Bio, ensuring that financial risks are managed prudently while aiming for potential breakthroughs.

In conclusion, while their current fiscal state may seem tenuous, Mustang Bio demonstrates a resilient outlook signifying growth potential. This inclination, owing to FDA’s support, channels hopeful yet cautious optimism from both Mustang’s strategic council and the trading fraternity, as the horizon before them unfolds rich in opportunity.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:


How much has this post helped you?



Leave a reply

Author card Timothy Sykes picture

Bryce Tuohey

Mentor and Trainer at StocksToTrade.com, Lead Mentor at Small Cap Rockets and To The Moon Report
Bryce’s first pattern was buying into strength in breakouts. But he noticed when they didn’t work, he took bigger losses. When the OTC market got hot, Bryce learned to dip buy the inevitable panics. He adapted his breakout strategy and now buys consolidation and trend breaks. His goal is to have better risk/reward and get an entry before multi-day listed breakouts.
Read More

In this article (YTD Performance)


* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”

ts swipe photo
Join Thousands Profiting From Smart Trades!
TRADE LIKE TIM
notification icon
Subscribe to receive notifications